I. 本實驗證實 C. tropicalis 中 FCY2 的 LOH 現象與 5-FC 抗藥性有 關，但仍有兩種可能原因需釐清：第一，因第 91 個胺基酸的改變；第 二，因 promoter 於 -224 和 -69 的變化。首先，以 real-time PCR 比較 YM020291、YM020291-R1、YM020291-R2、FCY2 (273G)/FCY2 (273G) 同 質置換株 及 FCY2 (273T)/FCY2 (273T) 同質置換株等菌株的 FCY2 mRNA 表現量是否有差異，確認第二種可能性。或者以 site-directed mutagenesis 將同源重組質體 LOB319 (G 股) 的 FCY2 之核苷酸 273G 突變為 T，LOB320 (T 股) 的 273T 突變為 G，分別送入 YM020291 進 行同源置換後，進行感受性測詴，確認第一種可能性。
II. 由於 Legrand et al. 的研究指出 DNA repair pathway、genome instability 與藥物抗藥性是彼此相關 (Legrand et al., 2007)。推測本實驗於 FCY2 發 現 有 LOH 現象之六個臨床菌株也許在 DNA repair 的機制有缺陷，故 找出可能的 DNA repair 相關基因之進行研究，對 5-FC 敏感且不會產 生抗藥衍生株之臨床菌株進行相關基因剔除，測詴是否增加其產生抗藥 菌株之頻率。
III. 由於仍有菌株尚未發現其 5-FC 抗藥機制為何，代表 C. tropicalis 仍然 有其他的機制涉及 5-FC 抗藥，推測可能其他的機制有：第一，另一個 可能的 PCP 是 CTRG00460 序列突變造成的抗藥性，有待序列分析；
第二，還有其他 PCP 參與 5-FC 運送至菌體內的過程，找出具有同源 序列者，進行功能探討及研究；第三，除了 URA3 外的 pyrimidine de novo pathway 基因發生序列變化，或基因表現量改變，或者是還有其他 的途徑共同參與，以上都有可能是發生抗藥性的原因，有待更進一步的 研究。
IV. 第二部分之初步結果發現以 chloramphenical 及 kanamycin 為報導基 因之篩選性質體 LOB324 及 LOB325，於適當濃度之篩選抗生素培養基 具有想要之篩選效果，之後可以 error-prone PCR 產生隨機突變 DNA 片段之 pool，接入質體 LOB324 及 LOB325 進行測詴，是否於篩選抗 生素培養基中能剔除隨機突變 DNA 片段中 帶有 nonsense 及
frameshift mutations，以利日後的研究。
十三、參考文獻
Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin.
Infect. Dis. 24:1122-1128.
Akins RA. 2005. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol. 43(4):285-318.
Albertson GD, Niimi M, Cannon RD, Jenkinson HF. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother.
40(12):2835-41.
Basehoar AD, Zanton SJ, Pugh BF. 2004. Identification and distinct regulation of yeast TATA box-containing genes. Cell. 116(5):699-709.
Barker KS, Rogers PD. 2006. Recent Insights into the Mechanisms of Antifungal Resistance.
Curr Infect Dis Rep. 8(6):449-456.
Bennett JE. 1996. Antifungal agents. In Goodman &Gilman’s The Pharmacological Basis of Therapeutics, 9th edn, (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW & Goodman Gilman A., Eds), pp. 1175-90. McGraw-Hill, New York.
Berman J, Sudbery PE. 2002. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet. 3(12):918-30. Review.
Bruno VM, Mitchell AP. 2005. Regulation of azole drug susceptibility by Candida albicans protein kinase CK2. Mol Microbiol. 56(2):559-73.
Bustamante CI. 2005. Treatment of Candida infection: a view from the trenches! Curr Opin Infect Dis. 18(6):490-5. Review.
Cadwell RC, Joyce GF. 1992. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2(1):28-33.
Cadwell RC, Joyce GF. 1994. Mutagenic PCR. PCR Methods Appl. 3(6):S136-40.
Calderone RA, Fonzi WA. 2001. Virulence factors of Candida albicans. Trends Microbiol.
9(7):327-35. Review.
Calderone RA. (Ed.) 2002 Candida and Candidiasis. ASM Press, Washington, DC.
Carr LL, Gottschling DE. 2008. Does age influence loss of heterozygosity? Exp Gerontol.
43(3):123-9. Review.
Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. 1983. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 305(5937):779-84.
Chapeland-Leclerc F, Bouchoux J, Goumar A, Chastin C, Villard J, Noël T. 2005.
Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob Agents Chemother. 49(8):3101-8.
Chen CG, Yang YL, Shih HI, Su CL, Lo HJ. 2004. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother. 48(12):4505-12.
Chen YC, Chang SC, Luh KT, Hsieh WC. 2003. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother. 52(1):71-7.
Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. 1997. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol. 18(5):369-75.
Chevallier MR, Jund R, Lacroute F. 1975. Characterization of cytosine permeation in Saccharomyces cerevisiae. J Bacteriol. 122(2):629-41.
Chu S, Herskowitz I. 1998. Gametogenesis in yeast is regulated by a transcriptional cascade dependent on Ndt80. Mol Cell. 1(5):685-96.
Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, Warnock D, Morgan J; Brazilian Network Candidemia Study. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 44(8):2816-23.
Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, d'Enfert C, Berman J, Sanglard D. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell. 6(10):1889-904.
Coste A, Turner V, Ischer F, Morschhäuser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics. 172(4):2139-56.
Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell. 3(6):1639-52.
de Micheli M, Bille J, Schueller C, Sanglard D. 2002. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol Microbiol. 43(5):1197-214.
Desnos-Ollivier M, Bretagne S, Bernède C, Robert V, Raoux D, Chachaty E, Forget E, Lacroix C, Dromer F; Yeasts Group. 2008. Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France. Emerg Infect Dis. 14(4):557-65.
Diasio RB, Bennett JE, Myers CE. 1978. Mode of action of 5-fluorocytosine. Biochem Pharmacol. 27(5):703-7.
Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. 2004. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans.
Antimicrob Agents Chemother. 48(6):2223-7.
Dogra S, Krishnamurthy S, Gupta V, Dixit BL, Gupta CM, Sanglard D, Prasad R. 1999.
Asymmetric distribution of phosphatidylethanolamine in C. albicans: possible mediation by CDR1, a multidrug transporter belonging to ATP binding cassette (ABC) superfamily.
Yeast. 15(2):111-21.
Dunkel N, Blass J, Rogers PD, Morschhäuser J. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol.
69(4):827-40.
Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. 1999.
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 29(2):239-44.
Enjo F, Nosaka K, Ogata M, Iwashima A, Nishimura H. 1997. Isolation and characterization of a thiamin transport gene, THI10, from Saccharomyces cerevisiae. J Biol Chem. 272(31):19165-70.
Fasoli M, Kerridge D. 1988. Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species. Ann N Y Acad Sci. 544:260-3.
Ferreira T, Brèthes D, Pinson B, Napias C, Chevallier J. 1997. Functional analysis of mutated purine-cytosine permease from Saccharomyces cerevisiae. A possible role of the hydrophilic segment 371-377 in the active carrier conformation. J Biol Chem.
272(15):9697-702.
Ferreira T, Chevallier J, Napias C, Brèthes D. 1998. Role of the proline residue 376 in the catalytic activity of purine-cytosine permease of Saccharomyces cerevisiae. Folia Microbiol (Praha). 43(2):193.
Ferreira T, Chevallier J, Naplas C, Brèthes D. 1998. Role of the proline residue 376 in the catalytic activity of purine-cytosine permease of Saccharomyces cerevisiae. Folia Microbiol (Praha). 43(2):191-3.
Ferreira T, Chevallier J, Paumard P, Napias C, Brèthes D. 1999. Screening of an intragenic second-site suppressor of purine-cytosine permease from Saccharomyces cerevisiae. Possible role of Ser272 in the base translocation process. Eur J Biochem.
260(1):22-30.
Ferreira T, Napias C, Chevallier J, Brèthes D. 1999. Evidence for a dynamic role for proline376 in the purine-cytosine permease of Saccharomyces cerevisiae. Eur J Biochem.
263(1):57-64.
Fidel PL Jr, Vazquez JA, Sobel JD. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev.
12(1):80-96. Review.
Florent M, Noël T, Ruprich-Robert G, Da Silva B, Fitton-Ouhabi V, Chastin C, Papon N, Chapeland-Leclerc F. 2009. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in
clinical isolates of Candida lusitaniae. Antimicrob Agents Chemother. 53(7):2982-90.
Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhäuser J. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother. 42(12):3065-72.
Gaur NA, Puri N, Karnani N, Mukhopadhyay G, Goswami SK, Prasad R. 2004.
Identification of a negative regulatory element which regulates basal transcription of a multidrug resistance gene CDR1 of Candida albicans. FEMS Yeast Res. 4(4-5):389-99.
Georgiev, V.St. 1998 Infectious Diseases in Immunocomprised Hosts, CRC Press, Boca Raton, New York.
Georgopapadakou NH, Walsh TJ. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 40(2):279-91. Review.
Georgopapadakou NH. 2001. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs. 10(2):269-80. Review.
Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 37(9):1172-7.
Hernáez ML, Gil C, Pla J, Nombela C. 1998. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast.
14(6):517-26.
Hitchcock CA. 1991. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem Soc Trans. 19(3):782-7.
Review.
Hope WW, Tabernero L, Denning DW, Anderson MJ. 2004. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother.
48(11):4377-86.
Horn R, Wong B, Kiehn T E, Armstrong D. 1985. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 7:646–655.
Horsburgh CR Jr, Kirkpatrick CH. 1983. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med.
74(1B):23-9.
Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. 1996. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc. 95(1):19-28.
Jund R, Lacroute F. 1970. Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae. J Bacteriol. 102(3):607-15.
Karnani N, Gaur NA, Jha S, Puri N, Krishnamurthy S, Goswami SK, Mukhopadhyay G, Prasad R. 2004. SRE1 and SRE2 are two specific steroid-responsive modules of Candida drug resistance gene 1 (CDR1) promoter. Yeast. 21(3):219-39.
Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U,
Einsele H. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation.
FEBS Lett. 400(1):80-2.
Kern L, de Montigny J, Lacroute F, Jund R. 1991. Regulation of the pyrimidine salvage pathway by the FUR1 gene product of Saccharomyces cerevisiae. Curr Genet. 19(5):333-7.
Komshian SV, Uwaydah AK, Sobel JD, Crane LR. 1989. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 11:379–390.
Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, Bodey GP, Raad II. 2001. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin.
Infect. Dis. 33:1676-1681.
Krishnamurthy S, Gupta V, Prasad R, Panwar SL, Prasad R. 1998. Expression of CDR1, a multidrug resistance gene of Candida albicans: transcriptional activation by heat shock, drugs and human steroid hormones. FEMS Microbiol Lett. 160(2):191-7.
Krishnamurthy S, Gupta V, Snehlata P, Prasad R. 1998. Characterisation of human steroid hormone transport mediated by Cdr1p, a multidrug transporter of Candida albicans, belonging to the ATP binding cassette super family. FEMS Microbiol Lett. 158(1):69-74.
Lamp KC, Freeman CD, Klutman NE, Lacy MK. 1999. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet.
36(5):353-73. Review.
Legrand M, Chan CL, Jauert PA, Kirkpatrick DT. 2007. Role of DNA mismatch repair and double-strand break repair in genome stability and antifungal drug resistance in Candida albicans. Eukaryot Cell. 6(12):2194-205.
Letscher-Bru V, Herbrecht R. 2003. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother. 51(3):513-21. Review.
Leung DW, Chen E, Goeddel DV. 1989. A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction. Technique 1:11-15.
Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. 2002. Molecular basis of resistance to azole antifungals. Trends Mol Med. 8(2):76-81. Review.
Marr KA, Seidel K, White TC, Bowden RA. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
Miller LG, Hajjeh RA, Edwards JE Jr. 2001. Estimating the cost of nosocomial candidemia in the united states. Clin Infect Dis. 32(7):1110.
National Committee for Clinical and Laboratory Standards Institute (NCCLS). 1997.
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts;
Approved Standard, CLSI, M27A. Wayne, PA.
National Committee for Clinical Laboratory Standards (NCCLS). 2002. Publication Of
M27-A2: reference method for broth dilution antifungal susceptibility testing of yeasts:
approved standard–second edition. 22:1–29.
Niimi M, Niimi K, Takano Y, Holmes AR, Fischer FJ, Uehara Y, Cannon RD. 2004.
Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J Antimicrob Chemother. 54(6):999-1006.
Odds F C. 1988. Ecology of Candida and epidemiology of canddidosis. Candida and candidosis: a review and bibliography. 2nd ed. London, United Kingdom: Bailliére Tindall pp. 68-82.
Paluszynski JP, Klassen R, Rohe M, Meinhardt F. 2006. Various cytosine/adenine permease homologues are involved in the toxicity of 5-fluorocytosine in Saccharomyces cerevisiae. Yeast. 23(9):707-15.
Papon N, Noël T, Florent M, Gibot-Leclerc S, Jean D, Chastin C, Villard J, Chapeland-Leclerc F. 2007. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob Agents Chemother. 51(1):369-71.
Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 45(10):2676-84.
Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 20(1):133-63. Review.
Pfaller MA, Segreti J. 2006. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis. 42 Suppl 4:S153-63.
Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. 2001. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother. 46(11):3518-21.
Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. 1987. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur. J. Clin. Microbiol.
6:628-633.
Polak A, Grenson M. 1973. Interference between the uptake of pyrimidines and purines in yeasts. Pathol Microbiol (Basel). 39(1):37-8.
Polak A, Scholer HJ. 1980. Mode of action of 5-fluorocytosine. Revue de I’lnstitute Pasteur de lyon 13:233-44.
Polak A, Wain WH. 1977. The influence of 5-fluorocytosine on nucleic acid synthesis in Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus. Chemotherapy.
23(4):243-59.
Polak A. 1977. 5-Fluorocytosine--current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol. 4:158-67.
Prasad R, Murthy SK, Gupta V, Prasad R. 1995. Multiple drug resistance in Candida albicans. Acta Biochim Pol. 42(4):497-504. Review.
Pujol C, Reynes J, Renaud F, Raymond M, Tibayrenc M, Ayala FJ, Janbon F, Mallié M, Bastide JM. 1993.The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. PNAS. U S A.
90(20):9456-9.
Puri N, Krishnamurthy S, Habib S, Hasnain SE, Goswami SK, Prasad R. 1999. CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole. FEMS Microbiol Lett. 180(2):213-9.
Radding JA, Heidler SA, Turner WW. 1998. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans.
Antimicrob Agents Chemother. 42(5):1187-94.
Rangel-Frausto M S, Wiblin T, Blumberg H M, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards J E, Jr, Jarvis W, Dawson J, Wenzel R P. 1999. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 29:253–258.
Rasila TS, Pajunen MI, Savilahti H. 2009. Critical evaluation of random mutagenesis by error-prone PCR protocols, Escherichia coli mutator strain and hydroxylamine treatment.
Anal Biochem. [Epub ahead of print]
Rex JH, Rinaldi MG, Pfaller MA. 1995. Resistance of Candida species to fluconazole.
Antimicrob Agents Chemother. 39(1):1-8. Review.
Ryder NS. 1992. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 126 Suppl 39:2-7. Review.
Ruan SY, Hsueh PR. 2009. Invasive candidiasis: an overview from taiwan. J Formos Med Assoc. 108(6):443-51.
Saini P, Prasad T, Gaur NA, Shukla S, Jha S, Komath SS, Khan LA, Haq QM, Prasad R.
2005. Alanine scanning of transmembrane helix 11 of Cdr1p ABC antifungal efflux pump of Candida albicans: identification of amino acid residues critical for drug efflux. J Antimicrob Chemother. 56(1):77-86.
Sandford, GR, Merz W G, Wingard JR, Charache P., and Saral R. 1980. The value of fungal surveillance cultures as predictors of systemic fungal infections. J. Infect. Dis.
142:503-509.
Sanglard D, Ischer F, Calabrese D, Micheli M, Bille J. 1998. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updat. 1(4):255-65.
Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology. 143 ( Pt 2):405-16.
Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 39(11):2378-86.
Schmidt R, Manolson MF, Chevallier MR. 1984. Photoaffinity labeling and characterization of the cloned purine-cytosine transport system in Saccharomyces cerevisiae. PNAS. U S A. 81(20):6276-80.
Scholer HJ. 1980. Flucytosine. In Antifungal Chemotherapy, (Speller, D. C. E., Ed ), pp.35-106. Willey, Chichester.
Schumacher MA, Bashor CJ, Song MH, Otsu K, Zhu S, Parry RJ, Ullman B, Brennan RG. 2002. The structural mechanism of GTP stabilized oligomerization and catalytic activation of the Toxoplasma gondii uracil phosphoribosyltransferase. PNAS. U S A.
99(1):78-83.
Schumacher MA, Carter D, Scott DM, Roos DS, Ullman B, Brennan RG. 1998. Crystal structures of Toxoplasma gondii uracil phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding. EMBO J. 17(12):3219-32.
Séron K, Blondel MO, Haguenauer-Tsapis R, Volland C. 1999. Uracil-induced down-regulation of the yeast uracil permease. J Bacteriol. 181(6):1793-800.
Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin Microbiol Rev. 12(1):40-79.
Stolz J, Vielreicher M. 2003. Tpn1p, the plasma membrane vitamin B6 transporter of Saccharomyces cerevisiae. J Biol Chem. 278(21):18990-6.
Tkacz JS, DiDomenico B. 2001. Antifungals: what's in the pipeline. Curr Opin Microbiol.
4(5):540-5. Review.
Vanden Bossche H, Marichal P, Odds FC. 1994. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2(10):393-400. Review.
Vanden Bossche H, Willemsens G, Marichal P. 1987. Anti-Candida drugs--the biochemical basis for their activity. Crit Rev Microbiol. 15(1):57-72.
van't Wout J W. 1996. Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis. 15:238–242.
Vermes A, Guchelaar HJ, Dankert J. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 46(2):171-9. Review.
Vermitsky JP, Edlind TD. 2004. Azole resistance in Candida glabrata: coordinate
Vermitsky JP, Edlind TD. 2004. Azole resistance in Candida glabrata: coordinate